Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.36 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.36 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7764663 | 0.82 | CA1 (0.56) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL30839876 | 0.78 | CA1 (0.46) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL11726927 | 0.73 | CA1 (0.44) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL29707614 | 0.71 | CA1 (0.43) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL29779360 | 0.70 | CA1 (0.41) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL2117133 | 0.67 | CA1 (0.48) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL60308 | 0.64 | — | — | |
| SCHEMBL1774205 | 0.64 | — | — | |
| SCHEMBL14805672 | 0.64 | CA1 (0.45) | CA1ALDH1A1LMNACYP1A2YTHDF3 | |
| SCHEMBL10846658 | 0.63 | LMNA (0.59) | CA1ALDH1A1LMNACYP1A2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0177574-B1 | AMINOCARNITINES | CORNELL RESEARCH FOUNDATION, INC. (US) | 1989-12-20 | — | — | EP | claimed |
| US-4781863-A | FROM 6-CHLOROMETHYLURACIL | CORNELL RESEARCH FOUNDATION, INC. (US) | 1988-11-01 | — | — | US | claimed |
| US-20080039531-A1 | Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders | STRACHER ALFRED | 2008-02-14 | — | — | US | disclosed |
| US-5876747-A | CARNITINE, AMINOCARNITINE AND CYSTEIC ACID AS CARRIERS | CEPTOR CORPORATION | 1999-03-02 | — | — | US | disclosed |
| EP-0279887-B1 | Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder | STRACHER ALFRED (US) | 1995-02-01 | — | — | EP | disclosed |
| US-5008288-A | Skeletal & heat muscle disorders | CEPTOR CORPORATION | 1991-04-16 | — | — | US | disclosed |
| EP-0177574-B1 | AMINOCARNITINES | CORNELL RESEARCH FOUNDATION, INC. (US) | 1989-12-20 | — | — | EP | disclosed |
| US-4866040-A | DRUG COVALENTLY BONDED TO AMINOCARNITINE FOR DELIVERY TO SPECI FIC SITES | CEPTOR CORPORATION | 1989-09-12 | — | — | US | disclosed |
| EP-0279887-A2 | Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder | Stracher, Alfred (US) | 1988-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039531-A1 | Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders | CPT1B, CAPNS1, CAPN1 | CA1 646/4885ALDH1A1 63/4885LMNA 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.